ArticleCureus2025
A Clinico-Epidemiological Study of Various Autoimmune Vesiculobullous Disorders in a Tertiary Care Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Pemphigus and pemphigoid disorders, as well as dermatitis herpetiformis, are all part of the diverse group of conditions known as autoimmune vesiculobullous/blistering disorders (AIBDs). These disorders are caused by autoantibodies that target intercellular or cell-matrix adhesion proteins and are clinically characterized by blisters or erosions of the skin and/or mucous membranes. The incidence peaks at 30-60 years with an equal incidence in men and women. There are 0.1 to 0.5 cases of pemphigus for every 100,000 people. Materials and methods This single-center retrospective observational study was conducted at our tertiary care center (Great Eastern Medical School and Hospital) in Srikakulam, Andhra Pradesh, India, between March 2018 and March 2025, and examined 50 histopathologically and direct immunofluorescence confirmed cases of autoimmune vesiculobullous disorders over a seven-year period. Results The percentage of females, i.e., 28 (56%) out of 50 individuals, is marginally higher than that of males (22 (44%)). The most prevalent age group is 51-60 years old (26%), followed by 41-50 years old (20%). The majority of cases are from rural areas (72%) and are occupied by people from low socioeconomic backgrounds (72%). The majority of farmers are local residents (76%) with few migrants (24%). Of the 50 cases, the most prevalent intraepidermal variants were pemphigus vulgaris (18 cases) and pemphigus foliaceus (nine cases), with a single case of pemphigus vegetans, whereas the most prevalent sub-epidermal variants were bullous pemphigoid (14 cases), with a small number of epidermolysis bullosa acquisita cases (eight cases). In 44% of instances, mucosal involvement is observed. Comorbidities, such as diabetes, hypertension, heart disease, and malignancies, were found in a small percentage of cases. Corticosteroids were the first line of treatment, and immunosuppressants were used for maintenance. Few patients had positive outcomes using dexamethasone cyclophosphamide pulse therapy (DCP), and rituximab given in two cases showed disease control after the second dose. Better disease control was demonstrated by patients who adhered to the long-term treatment. Conclusion In recent years, autoimmune vesiculobullous illnesses have become more prevalent and are significantly correlated with other systemic conditions. A difficult problem that requires careful handling is atypical clinical manifestations, which can be linked to inappropriate and delayed treatment as well as noncompliance. Long-term steroid medication is less necessary with early diagnosis, which further minimizes consequences by evaluating the disease activity and severity and starting a targeted treatment. For the general improvement of quality of life, public education, development of medical services in rural regions, and the elimination of social stigma are, therefore, crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.